{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T16:04:23Z","timestamp":1791043463965,"version":"4.1.0"},"reference-count":33,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2011,1,4]],"date-time":"2011-01-04T00:00:00Z","timestamp":1294099200000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2011,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>It has been understood for some time that the treatment outcome of hepatitis C virus (HCV) infection is influenced by host genetic factors. Three independent genome\u2010wide association studies have recently identified that a genetic variation in the<jats:italic>IL28B<\/jats:italic>gene [interferon\u2010\u03bb3 (IFN\u2010\u03bb3)] determines the outcome of IFN\u2010\u03b1\u2010based therapy in patients with genotype 1 chronic hepatitis C infection. This genetic polymorphism is also strongly associated with a higher likelihood of spontaneous clearance following acute hepatitis C infection. These results confirm the importance of specific host genetic markers in predicting outcome and treatment response. They also provide the framework and potential for a clinically relevant and meaningful pharmacogenomic approach to personalizing anti\u2010HCV treatment.<\/jats:p>","DOI":"10.1111\/j.1478-3231.2010.02389.x","type":"journal-article","created":{"date-parts":[[2011,1,4]],"date-time":"2011-01-04T15:16:48Z","timestamp":1294154208000},"page":"29-35","source":"Crossref","is-referenced-by-count":22,"title":["The role of genetic markers in hepatitis C virus therapy: a major step for individualized care"],"prefix":"10.1111","volume":"31","author":[{"given":"John G.","family":"McHutchison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,1,4]]},"reference":[{"key":"e_1_2_13_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808010"},{"key":"e_1_2_13_3_2","first-page":"958","article-title":"Peginterferon alfa\u20102b plus ribavirin compared with interferon alfa\u20102b plus ribavirin for initial treatment of chronic hepatitis C","volume":"358","author":"Manns MP","year":"2001","journal-title":"a randomised trial"},{"key":"e_1_2_13_4_2","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.1002\/hep.1840360730","article-title":"Side effects of therapy of hepatitis C and their management","volume":"36","author":"Fried MW.","year":"2002","journal-title":"Hepatology"},{"key":"e_1_2_13_5_2","first-page":"346","article-title":"Peginterferon\u2010alpha2a and ribavirin combination therapy in chronic hepatitis C","volume":"140","author":"Hadziyannis SJ","year":"2004","journal-title":"a randomized study of treatment duration and ribavirin dose"},{"key":"e_1_2_13_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032502"},{"key":"e_1_2_13_7_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.06.008"},{"key":"e_1_2_13_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805062"},{"key":"e_1_2_13_9_2","first-page":"1260","article-title":"Pegylated interferon\u2010alpha\u20102a plus ribavirin for treatment\u2010naive Asian patients with hepatitis C virus genotype 1 infection","volume":"47","author":"Liu CH","year":"2008","journal-title":"a multicenter, randomized controlled trial"},{"key":"e_1_2_13_10_2","first-page":"1259","article-title":"Southeast Asian patients with chronic hepatitis C","volume":"36","author":"Dev AT","year":"2002","journal-title":"the impact of novel genotypes and race on treatment outcome"},{"key":"e_1_2_13_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature08309"},{"key":"e_1_2_13_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.449"},{"key":"e_1_2_13_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.447"},{"key":"e_1_2_13_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.299.11.1335"},{"key":"e_1_2_13_15_2","first-page":"548","article-title":"DNA polymorphisms and response to treatment in patients with chronic hepatitis C","volume":"49","author":"Morgan TR","year":"2008","journal-title":"results from the HALT-C trial"},{"key":"e_1_2_13_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22877"},{"key":"e_1_2_13_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2370.2004.00478.x"},{"key":"e_1_2_13_18_2","first-page":"404","article-title":"Interleukin\u20101, interleukin\u201010 and tumour necrosis factor\u2010alpha gene polymorphisms in hepatitis C virus infection","volume":"22","author":"Constantini PK","year":"2002","journal-title":"an investigation of the relationships with spontaneous viral clearance and response to alpha-interferon therapy"},{"key":"e_1_2_13_19_2","doi-asserted-by":"publisher","DOI":"10.1086\/498244"},{"key":"e_1_2_13_20_2","doi-asserted-by":"publisher","DOI":"10.1159\/000073218"},{"key":"e_1_2_13_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(01)00243-4"},{"key":"e_1_2_13_22_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.22347"},{"key":"e_1_2_13_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(03)00029-9"},{"key":"e_1_2_13_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.04.011"},{"key":"e_1_2_13_25_2","doi-asserted-by":"publisher","DOI":"10.1159\/000025035"},{"key":"e_1_2_13_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2004.00509.x"},{"key":"e_1_2_13_27_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.08.036"},{"key":"e_1_2_13_28_2","article-title":"Differential association of a chromosome 19 single nucleotide polymorphism (SNP RS12979869) to outcome (early and sustained virological response (EVR\/SVR)) in na\u00efve vs retreated HCV patients treated with IFN\u2010based therapies","volume":"52","author":"Asselah T","year":"2010","journal-title":"Hepatology"},{"key":"e_1_2_13_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature08463"},{"key":"e_1_2_13_30_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.12.056"},{"key":"e_1_2_13_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22729"},{"key":"e_1_2_13_32_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2007.128611"},{"key":"e_1_2_13_33_2","first-page":"373","article-title":"IFN\u2010lambda","volume":"26","author":"Ank N","year":"2006","journal-title":"novel antiviral cytokines"},{"key":"e_1_2_13_34_2","first-page":"729","article-title":"IL\u201028 and IL\u201029","volume":"89","author":"Uze G","year":"2007","journal-title":"newcomers to the interferon family"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1478-3231.2010.02389.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1478-3231.2010.02389.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T11:22:49Z","timestamp":1740828169000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1478-3231.2010.02389.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":33,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["10.1111\/j.1478-3231.2010.02389.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1478-3231.2010.02389.x","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}